Savara Inc., a clinical stage biopharmaceutical company specializing in rare respiratory diseases, has announced the issuance of inducement awards to two newly hired employees. As of July 15, 2025, these awards include options to purchase a total of 20,000 shares of Savara's common stock, with an exercise price of $2.29 per share, and restricted stock units (RSUs) for an additional 20,000 shares. These awards are part of the Savara Inc. 2021 Inducement Equity Incentive Plan and are granted under NASDAQ Listing Rules. The stock options have a term of 10 years and vest quarterly over four years, while the RSUs will fully vest on the two-year anniversary of employment, contingent upon the employees' continued tenure with the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.